Statistics from Altmetric.com
Correspondence to: Jing-Ping Zhao, Mental Health Institute of the Second Xiangya Hospital, Central South University, 410011, 139 Renmin Middle Road, Changsha, Hunan, China; firstname.lastname@example.org
How effective are a lifestyle intervention and metformin—alone and in combination—at reducing antipsychotic-induced weight gain in adults?
128 people aged 18–45 years with a first psychotic episode of schizophrenia (according to DSM-IV). Inclusions: weight gain of more than 10% of their pre-drug body weight within the first year of treatment with a targeted antipsychotic agent (clozapine, olanzapine, risperidone, or sulpiride), documented weight and treatment history, relatively stable improvement (PANSS ⩽60), taking only 1 antipsychotic at a stable dose (changed by <25% in the past 3 months), under care of parent or guardian who monitored food, exercise, medication intake. Exclusions: evidence of liver or renal dysfunction, cardiovascular disease, diabetes mellitus, substance abuse, psychiatric diagnosis other than schizophrenia, or other conditions that limited ability to perform lifestyle modifications.
Outpatient clinic of the Mental Health Institute of the Second Xiangya Hospital at Central South University in China; recruitment October 2004 to December 2006. …
Source of funding: National Key Technologies R&D Program and from the Ministry of Science and Technology of the People’s Republic of China.
▸ Additional notes, a table and references are published online only at http://ebmh.bmj.com/content/vol11/issue3
Competing interests: MW has been a consultant for Alamo and Shire Pharmaceuticals, and has received funding from Pfizer..
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.